Media ReleasesRadiopharm Theranostics

View All Radiopharm Theranostics News

Radiopharm receives $1.9M advance on FY24 R&D tax incentive

Sydney, Australia – 21 February 2024 – Radiopharm Theranostics Limited (ASX:RAD), a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has received $1,900,000 from Radium Capital under a funding facility secured against Radiopharm’s anticipated FY24 Research and Development Tax Incentive (RDTI).

The funds will support the clinical trial pipeline and otherwise for general working capital of the Company.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?